Plain-English translation of NCT06513819 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a pilot study testing a new way to help people living with HIV who drink alcohol and take five or more medications. A clinical pharmacist will work with you one-on-one to review all your medications, understand how they interact with alcohol, and help you use them safely. The goal is to prevent falls, reduce harmful medication interactions, and improve your overall health.
Many people with HIV take multiple medications that can have serious side effects—especially when combined with alcohol. These effects can include dizziness, confusion, and falls. This study wants to see if a pharmacist can help catch and prevent these problems before they hurt you.
You likely qualify if…
You likely don't qualify if…
You'll start with a phone call from the research team to answer questions about your alcohol use and confirm you're interested. A few days later, a pharmacist will call you for about 15–20 minutes to review all your medications. You'll also complete a home blood test kit (finger prick) and fill out a survey, which you'll mail back. The whole process is brief and happens mostly by phone and mail from your home.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Yale University
Collaborators
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Enrollment target
~100 participants
Started
January 2025
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
50 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Amy C Justice, MD, PhD
Yale University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.